v3.26.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Current assets:    
Cash and cash equivalents $ 4,868 $ 18,618
Accounts receivable 2,042 2,042
Marketable securities 48,523 31,091
Prepaid expenses and other current assets 1,090 1,570
Total current assets 56,523 53,321
Property and equipment, net 525 736
Operating lease right-of-use asset 3,549 4,318
Other assets 246 246
Total assets 60,843 58,621
Current liabilities:    
Accounts payable 1,049 309
Accrued expenses and other current liabilities 3,137 3,943
Current portion of deferred revenue 5,123 6,831
Current portion of operating lease liability 1,329 1,586
Total current liabilities 10,638 12,669
Long-term deferred revenue 0 1,708
Operating lease liability, less current portion 2,220 2,732
Total liabilities 12,858 17,109
Commitments and contingencies (Note 12)
Stockholders' equity:    
Preferred stock, $0.0001 par value - 20,000 shares authorized; none issued and outstanding as of June 30, 2026 and December 31, 2025 0 0
Additional paid-in capital 186,255 165,578
Accumulated other comprehensive gain (30) 1
Accumulated deficit (147,004) (132,580)
Total stockholders' (deficit)/equity attributable to Rani Therapeutics Holdings, Inc. 39,234 33,010
Non-controlling interest 8,751 8,502
Total stockholders' (deficit)/equity 47,985 41,512
Total liabilities and stockholders' equity 60,843 58,621
Common Class A    
Stockholders' equity:    
Common stock, value 11 9
Common Class B    
Stockholders' equity:    
Common stock, value 2 2
Common Class C    
Stockholders' equity:    
Common stock, value $ 0 $ 0